European Commission Approval for Janssen’s Preventive Ebola Vaccine

Share it with your friends Like

Thanks! Share it with your friends!


Since the height of the West African Ebola epidemic in 2014—the worst outbreak in the disease’s history—we have worked to accelerate efforts to develop an Ebola vaccine. Yesterday, Janssen Pharmaceuticals, Inc. received the first approval of its Ebola vaccine regimen from the Marketing Authorization from the European Commission, which is the executive arm of the European Union.

Watch & discover the steps that J&J has taken toward enabling broader access to its vaccine regimen for the people who need it most, and the lessons learned from the vaccine’s development that could help in the fight against COVID-19.

Subscribe to JNJ on YouTube:
J&J on Facebook:
JNJ News on Twitter:
J&J on LinkedIn:
J&J’s Latest News:


Write a comment